Trust Point Inc. Buys New Stake in Medpace Holdings, Inc. (NASDAQ:MEDP)

Trust Point Inc. bought a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 4,894 shares of the company's stock, valued at approximately $1,500,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of MEDP. Rice Hall James & Associates LLC grew its position in Medpace by 12.1% in the first quarter. Rice Hall James & Associates LLC now owns 183,556 shares of the company's stock valued at $30,028,000 after acquiring an additional 19,884 shares during the last quarter. Cambridge Investment Research Advisors Inc. grew its position in Medpace by 28.3% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 1,581 shares of the company's stock valued at $259,000 after acquiring an additional 349 shares during the last quarter. Cetera Advisor Networks LLC grew its position in Medpace by 26.1% in the first quarter. Cetera Advisor Networks LLC now owns 2,304 shares of the company's stock valued at $377,000 after acquiring an additional 477 shares during the last quarter. Rhumbline Advisers grew its position in Medpace by 2.4% in the first quarter. Rhumbline Advisers now owns 78,755 shares of the company's stock valued at $12,884,000 after acquiring an additional 1,827 shares during the last quarter. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its position in Medpace by 10.5% in the first quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 10,537 shares of the company's stock valued at $1,724,000 after acquiring an additional 1,005 shares during the last quarter. Institutional investors own 77.98% of the company's stock.

Medpace Trading Up 0.9 %

MEDP stock traded up $3.61 during trading on Wednesday, hitting $396.12. The company had a trading volume of 183,642 shares, compared to its average volume of 249,252. The business has a 50-day moving average of $374.45 and a 200-day moving average of $308.44. Medpace Holdings, Inc. has a one year low of $185.43 and a one year high of $419.42. The stock has a market cap of $12.18 billion, a PE ratio of 44.61, a PEG ratio of 2.10 and a beta of 1.38.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its earnings results on Monday, February 12th. The company reported $2.46 EPS for the quarter, beating the consensus estimate of $2.22 by $0.24. Medpace had a return on equity of 63.98% and a net margin of 15.00%. The business had revenue of $498.40 million for the quarter, compared to analysts' expectations of $498.72 million. During the same period in the prior year, the business posted $2.12 earnings per share. The firm's revenue was up 26.5% on a year-over-year basis. Research analysts forecast that Medpace Holdings, Inc. will post 10.53 EPS for the current year.

Insider Activity at Medpace

In other Medpace news, major shareholder Medpace Investors, Llc sold 50,000 shares of the business's stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $391.75, for a total value of $19,587,500.00. Following the transaction, the insider now directly owns 5,539,947 shares of the company's stock, valued at $2,170,274,237.25. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other Medpace news, VP Susan E. Burwig sold 102 shares of the business's stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $403.00, for a total value of $41,106.00. Following the transaction, the vice president now directly owns 15,181 shares of the company's stock, valued at $6,117,943. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, major shareholder Medpace Investors, Llc sold 50,000 shares of the company's stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $391.75, for a total value of $19,587,500.00. Following the transaction, the insider now directly owns 5,539,947 shares in the company, valued at $2,170,274,237.25. The disclosure for this sale can be found here. Insiders have sold 189,340 shares of company stock worth $76,651,647 over the last ninety days. Insiders own 25.70% of the company's stock.

Analyst Ratings Changes

Several analysts have recently weighed in on MEDP shares. Robert W. Baird boosted their price target on Medpace from $312.00 to $408.00 and gave the stock an "outperform" rating in a report on Wednesday, February 14th. UBS Group upgraded Medpace from a "neutral" rating to a "buy" rating and boosted their price target for the stock from $282.00 to $452.00 in a report on Thursday, February 15th. Deutsche Bank Aktiengesellschaft started coverage on Medpace in a report on Monday, March 18th. They set a "hold" rating and a $395.00 price target on the stock. Finally, StockNews.com cut Medpace from a "buy" rating to a "hold" rating in a report on Saturday, March 23rd. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $382.00.

Medpace Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.